Immatics US, Inc. was launched in 2015 by Immatics Biotechnologies GmbH and MD Anderson Cancer Center.
MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center, located in Houston on the campus of the Texas Medical Center, is one of the world’s largest and most respected centers devoted exclusively to cancer patient care, research, education and prevention. The Texas Legislature created MD Anderson in 1941 as part of The University of Texas System. It is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971. U.S. News & World Report’s “Best Hospitals” survey has ranked MD Anderson the nation’s top hospital for cancer care. MD Anderson has been ranked the leading cancer hospital for 11 of the past 14 years. The institution has been named one of the nation’s top two hospitals for cancer care every year since the survey began in 1990.
In Fiscal Year 2014, more than 127,000 people sought the superior care that has made the institution so widely respected. More than 8,000 participants were enrolled in clinical trials exploring innovative treatments. MD Anderson’s cancer clinical trial program is the largest in the nation. In FY14, MD Anderson invested more than $735 million in research, an increase of 35% in the past five years.
MD Anderson’s mission is to eliminate cancer in Texas, the nation and the world through exceptional programs that integrate patient care, research and prevention. Its mission also includes education for undergraduate and graduate students, trainees, professionals, employees and the public.